PT - JOURNAL ARTICLE AU - Shaw, Reid AU - Haque, Ali R. AU - Fitzsimons, Jack AU - Hamidi, Adam AU - O’Connor, Timothy E. AU - Roloff, Gregory W. AU - Bemiss, Bradford C. AU - Kallwitz, Eric R. AU - Hagen, Patrick A. AU - Berg, Stephanie TI - Multicenter analysis of immunosuppressive medications on the subsequent risk of malignancy in solid organ transplant recipients AID - 10.1101/2022.12.02.22283027 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.02.22283027 4099 - http://medrxiv.org/content/early/2022/12/04/2022.12.02.22283027.short 4100 - http://medrxiv.org/content/early/2022/12/04/2022.12.02.22283027.full AB - Solid organ transplant is a curative treatment for end organ disease. However, the immunosuppressive therapy required to prevent graft rejection increases the likelihood of developing a subsequent malignancy. This retrospective cohort study from a multi-center academic hospital system investigated solid organ transplantation, immunosuppression, and the risk of subsequent malignancy. Of the 5,591 patients and 6,142 transplanted organs studied, there were 517 subsequent malignancies identified. Skin cancer was the most common type of malignancy to be diagnosed, whereas liver cancer was the first malignancy to present at a median time of one-year post-transplant. Subsequent malignancy was proportionally more often diagnosed in non-Hispanic White transplant recipients compared to other racial groups. Heart and lung transplant recipients had relatively higher rates of subsequent malignancy than liver and kidney transplant recipients, but this finding was not significant upon adjusting for immunosuppressive medications. Multivariate cox proportional hazard analysis and random forest variable importance calculations identified statistically significant correlations with sirolimus and azathioprine and high rates of malignancy after transplant, while tacrolimus was associated with low rates of post-transplant neoplasia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB exempt per Loyola University Medical Center IRB committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available not currently available.SOTsolid organ transplantEHRelectronic health recordICDinternational classification of diseaseHRhazard ratioCIconfidence intervalMLmachine learningmTORmammalian target of rapamycin